Though the body of literature is smaller for prioritizing MHC class II-restricted neoantigens, tools are available to predict the expression of the neoantigen, the percentage of the tumor that contains the neoantigen of interest, the N/C-terminal cleavage potential, the potential to bind the MHC class II molecule, and the potential to be recognized by a CD4+ TCR (summarized in Figure 5). The gene discussed is CD4; the disease is neoplasm.